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Rebuttal for manuscript #EN-16-1755 entitled: “RAMP2 influences glucagon receptor 
pharmacology via trafficking and signalling”. 
 
Editor’s comment 
While the reviewers felt that your topic is important and interesting, and that your additions were 
excellent, they still have a few concerns that prevent acceptance of your manuscript in its present 
form. Their critiques indicate that additional data, experiments, and/or rewriting are required. All 
reviewer comments, appended below, require your careful consideration and appropriate response 
before the manuscript can be re-reviewed and considered for publication.  Specifically, in reading 
over the paper and the comments, it seems that the major concern is that only one stable cell line 
was used for these studies, which always brings up concerns about specificity of results (is this due 
to some off-target vaguery of the clone, or is it really generalizable?).  It should not be necessary to 
repeat every experiment, or use multiple cell lines -  just performing the suggested binding study on 
one additional stable cell line, which you must have generated when deriving the line here, would 
go a long way toward ruling out a clonal-specific effect. 
 
Authors’ response 
We appreciate the editor’s concern that only one stable cell line was used for the binding studies. 
Therefore, we have taken the editor’s advice and performed binding experiments in an independent 
cell line stable expressing RAMP2. Briefly: 
 
Methods: 
To ensure that these findings were attributable to co-expression of RAMP2 with the GCGR, rather 
than artefactual, a second cell line with RAMP2 stably upregulated was investigated (CHO-K1-GCGR-
CFP-RAMP2) and compared to a cell line transfected in parallel with a control (pcDNA3.1) plasmid. 
CHO-K1 cells expressing the human GCGR were co-transfected with C-terminally CFP-tagged RAMP2 
(Tebu-bio Ltd, UK) and a plasmid conferring puromycin resistance using lipofectamine 2000 (Thermo 
Fisher). Forty-eight hours later, media was supplemented with puromycin 10 μg/ml to select cells 
containing the construct. Expression was confirmed by qPCR. Whole cell binding assay was performed 
with CFP-RAMP2 stably transfected cells and controls transfected with pcDNA. I125glucagon was used 
as the competing peptide in all assays. Peptides were incubated with cells at room temperature for 90 
minutes. Counts were measured over 240s, normalised to maximal of each cell line and normalised to 
protein content of cells as determined by BCA assay. Receptor density (Bmax) was calculated using 
GraphPad Prism 7.0b (GraphPad Software Inc., USA) using the following regression fit line: 
Y=(Bmax*HotnM)/(HotnM + ColdNM + KdNM) + Bottom 
 
Results: 
Successful transfection of CHO-K1-GCGR cells with C-terminally CFP-tagged RAMP2 (Tebu-bio Ltd, UK) 
was confirmed by qPCR. H-RAMP2 was undetectable in the control cell line but expressed in the CHO-
K1-GCGR-CFP-RAMP2 cells. 
As with the first cell line (CHO-K1-GCGR-RAMP2), the binding affinity of glucagon for its receptor was 
not altered with the upregulation of RAMP2 (IC50 4.377nM with CFP-RAMP2 vs 5.123nM without 
(p=0.16)) (see Supplemental Figure 2A), however the density of GCGR binding sites (Bmax) was 
significantly lower in the cell line with upregulated RAMP2 (p=0.0069) (Supplemental Figure 2B).  
 
This data corroborates our initial binding data and we have now confirmed that the number of GCG 
Point-by Point Rebuttal
binding sites is reduced in the presence of RAMP2 in two independent stable cell lines. 
 
Amendments to manuscript: 
Methods: page 5 lines 131-134, page 6 lines 160-163 
Results: page 10 lines 288-290, 304-310 
Addition of Supplemental Figure 2  
 
 
Reviewer’s comment Authors’ response 
Reviewer 1  
1.     The authors need to alter the wording relating 
to "internalisation" throughout the manuscript. This 
has not actually been measured in this paper. They 
should use cellular distribution or similar instead. 
The confocal data for example show the presence of 
receptor/RAMP inside cells but this was measured at 
a single point in time and not in response to ligand. 
Therefore the authors cannot conclude that there is 
internalisation, rather than the receptor simply not 
reaching the cell surface. i.e. the authors could 
equally conclude that the receptor is trapped inside 
the cell by the RAMP.  
As suggested, internalisation has been rephrased 
throughout the manuscript. 
 
Amendments: Abstract page 2 line 55; Results 
page 12 line 368-369; Figure Legend page 21 line 
706 
2.      The binding data are now much clearer. 
However, the authors should not refer to binding 
data as "total binding", if in fact it is specific binding. 
The relevant text and figures need to be changed to 
deal with this. 
As suggested, total binding has been corrected to 
specific binding. 
 
Amendments: Methods page 6 line 150, line 154; 
Results page 10 lines 292-293, Discussion Page 13 
line 389; Figure Legend page 20 line 663 
3.      Page 3 line 92, reference 17 McLatchie does 
not report seven different receptors. Use Poyner et 
al 2002, Pharm Rev. instead. They have used 27 for 
17 later (p15) as well. The references need to be 
carefully checked. 
The references have been corrected and re-
reviewed.  
4.      The wording for G(X) on page 5 is unclear. The 
motivation for using this ligand is less important 
than being clear on its actual sequence. Is this 1-15 
glucagon together with 16-34 of exendin-4? Or is 
there more of a mix. Either reference the original 
sequence, explain more clearly or show the 
sequence in supplementary information. In order for 
any reader to reproduce the work, this is essential. 
The sequence of G(X) has been further clarified, 
however, the actual sequence cannot be disclosed 
for intellectual property reasons. 
 
Amendments: Methods page 5 line 112-119 
5.      There still seems to be some confusion around 
curve fitting parameters and inconsistency in the 
paper. The data from signalling assays appear to 
have been fit with a variable slope (4 parameter) but 
the equation implies that this was 3 parameter with 
a fixed slope of 1. This needs to be clarified. 
The curve fitting for the biphasic curves was done 
using a variable slope (four parameters) model. 
This has been clarified in the methods section. 
 
Amendments: Methods page 7 lines 201-203 
6.      All of the cell experiments use different 
conventions for reporting the cell number used, 
which is very confusing and does not allow 
The reporting of cell numbers has now been 
harmonised and numbers for cells/ml have been 
comparisons between assays. The actual cell number 
should be specified. Cells per mL is not acceptable if 
the volume pipetted into the well is not specified. 
recalculated to give cells/well.  
 
Amendments: Methods page 6 line 176, page 7 
line 187 
7.      Do not use "u" for micro. Use the correct 
symbol. This occurs in numerous places throughout 
the document. 
This has been corrected throughout. 
8.      On page 14, the speculation about the work 
showing bias should be removed and left until the 
description on page 15, which is adequate. As it 
stands, the work does not show bias. 
This has now been removed as suggested. 
9.      Table 1 should include statistical analysis. 
 
Statistical analysis was performed however none of 
the comparisons were statistically significant. This 
is described further in the results section. 
 
Amendments: Results Page 10 Lines 297-302 
 
10.     Table 3. If some of these experiments are less 
than n=3 as is suggested by the legend, then there 
should not be statistical analysis on these data. 
Statistical analysis was only carried out for 
experiments where n≥3. 
Reviewer 2  
1. The additional data that has been added improves 
the work and helps somewhat to support the 
interpretations. It will still be very important to 
quantify the GCGR on the cell surface by a method 
other than "total binding relative to control". Since 
you have performed competition binding of GCG 
radioligand and included IC50 data in Table 1, the 
homologous competition curves should be analyzed 
for Ki and Bmax values. This will be much more 
important and informative than what is shown in 
Figure 1. 
As explained above, Bmax has now been calculated 
for a second independent cell line. Ki is 
proportional to IC50 and therefore will be 
comparable with and without RAMP2. 
 
Amendments: 
Methods: page 5 lines 131-134, page 6 lines 160-
163 
Results: page 10 lines 288-290, 304-310 
Addition of Supplemental Figure 2  
 
2. Essentially all of the functional data presented can 
be explained by lower surface GCGR expression in 
the RAMP2 positive cell line than in the control cell 
line. It will be important to prepare and characterize 
several clonal lines with RAMP2 coexpression to be 
certain that the very low levels of GCGR in this line is 
reflective of the coexpression itself and not an 
artifact of the single clonal line studied.  
To ensure that these findings were attributable to 
co-expression of RAMP2 with the GCGR, rather 
than artefactual, a second cell line with RAMP2 
stably upregulated was investigated (CHO-K1-
GCGR-CFP-RAMP2) and compared to a cell line 
transfected in parallel with a control (pcDNA3.1) 
plasmid. Importantly, these findings corroborate 
those described in the first cell line. 
 
Amendments: 
Methods: page 5 lines 131-134, page 6 lines 160-
163 
Results: page 10 lines 288-290, 304-310 
Addition of Supplemental Figure 2  
3. It would be quite interesting to start with a stable 
RAMP2-expressing CHO cell line and a non-RAMP-
expressing CHO cell line and make stable GCGR-
The reviewer makes a good point, although we feel 
that this extensive work- not requested during the 
expressing lines from both via independent 
transfection to try to achieve clonal lines with similar 
surface GCGR expression. That would be quite 
interesting to study functionally. I understand that 
this would represent a substantial new effort.  
first round of review- is better served in another 
manuscript. Ideally, we would use CRISPR-Cas9 to 
delete/replace the endogenous loci in a beta or 
hepatocyte cell line, thus leading to stable and 
physiological GCGR expression levels in the 
presence or absence of RAMP. We have discussed 
this in the revised manuscript.  
 
Amendments: Discussion page 15 line 471-474  
4. The data set that best seems to support a 
mechanism for the reduction in cell surface receptor 
when RAMP gets coexpressed is figure 6 in which 
morphology is done on transfected HEK cells, and 
the RAMP-transected cells clearly had fluorescent 
receptor internalized. I fear that there could be 
glucagon in the serum used to culture these cells 
and the agonist-stimulated internalization response 
could be amplified in the presence of the RAMP. This 
could be quite interesting, but would require 
additional experiments. It would be helpful to 
perform this and other experiments in the absence 
of serum that could contain glucagon or other 
agonist. Another way to achieve this would be to 
perform the work in the presence of glucagon 
antagonist.  
The GCGR experiments performed in HEK cells 
were designed to corroborate the radioactive 
binding assays, rather than a complete work-up of 
receptor internalization mechanisms. In any case, 
we would not expect meaningful glucagon levels in 
FBS, since the fetus secretes high levels of insulin 
to counteract elevated maternal glucose 
concentration, and this would strongly inhibit 
alpha cell function. Additionally, glucagon-
stimulated GCGR internalization is known to be a 
high dose phenomenon, occurring at ≥1 µM (Roed 
et al JBC 2015), far above the known glucagon 
concentration in calves of 30-40 pM (Bloom et al, J 
Physiol, 1974). Thus the results are likely due to 
the interaction between non-bound/non-activated 
receptor and RAMP. The reviewer makes a 
reasonable point, however, and we discuss the 
requirement for future experiments with a GCGR 
antagonist or serum-free medium, or alternatively 
excess glucagon, in the revised manuscript.  
 
Amendments: Discussion page 15 line 451-454 
5. I am concerned that the differences being 
reported here from the literature may be a function 
of low level receptor expression that reflects clonal 
choice and/or hormone-stimulated internalization. I 
would like to see three additional sets of data to be 
convinced this is real. 1) independent clonal lines for 
the CHO-GCGR-RAMP2 expression to be sure the low 
level of surface receptor is real; 2) these lines need 
not only IC50 data for receptor binding, but also 
Bmax data to quantitatively determine receptor 
density; and 3) use of non-serum-containing medium 
or use of GCG antagonist to block agonist effect to 
downregulate the receptor. 
As described above, we have completed additional 
experiments to address points 1) and 2). 1) 
Independent clonal lines for CHO-GCGR-RAMP2 
expression confirm that the low level of surface 
receptor is real; 2) these lines provide IC50 data for 
receptor binding, but also Bmax data to 
quantitatively determine receptor density.  In 
terms of 3), we have inserted a caveat into the 
discussion re. GCGR antagonist, although as 
explained in response to the point above, the 
glucagon levels in FBS are expected to be far below 
the levels which have been demonstrated to be 
necessary to observe agonist-downregulation of 
the glucagon receptor. 
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ABSTRACT 39 
Endogenous satiety hormones provide an attractive target for obesity drugs. Glucagon causes weight 40 
loss by reducing food intake and increasing energy expenditure. To further understand the cellular 41 
mechanisms by which glucagon and related ligands activate the glucagon receptor (GCGR), we have 42 
investigated the interaction of the GCGR with RAMP2, a member of the family of Receptor Activity 43 
Modifying Proteins.  44 
 45 
We have used a combination of competition binding experiments, cell surface ELISA, functional 46 
assays assessing the Gαs and Gq pathways and β-arrestin recruitment, and siRNA knockdown to 47 
examine the effect of RAMP2 on the GCGR. Ligands tested were glucagon, glucagon-like peptide-1 48 
(GLP-1), oxyntomodulin and analogue G(X), a GLP-1/glucagon co-agonist developed in-house. 49 
Confocal microscopy was employed to assess whether RAMP2 affects the subcellular distribution of 50 
GCGR.  51 
 52 
Here we demonstrate that co-expression of RAMP2 and the GCGR results in reduced cell surface 53 
expression of the GCGR. This was confirmed by confocal microscopy, which demonstrated that 54 
RAMP2 co-localises with the GCGR and causes significant GCGR cellular redistribution. 55 
Furthermore, the presence of RAMP2 influences signalling through the Gαs and Gαq pathways, as 56 
well as recruitment of β-arrestin. This work suggests that RAMP2 may modify the agonist activity 57 
and trafficking of the GCGR, with potential relevance to production of new peptide analogues with 58 
selective agonist activities. 59 
 60 
 61 
  62 
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INTRODUCTION 63 
Gut and pancreatic hormones involved in appetite regulation are an attractive target for the 64 
development of drugs that aim to cause effective weight loss with minimal side effects. Glucagon has 65 
been shown to potently increase satiety and acutely reduce food intake in humans (1). Additionally, 66 
glucagon significantly increases energy expenditure in man (2-4). This, in association with the 67 
anorectic effects of glucagon (1), enhances its usefulness as an anti-obesity therapy.  68 
 69 
The glucagon receptor (GCGR) is a 7 transmembrane class B G-protein coupled receptor (GPCR). It 70 
classically activates adenylyl cyclase through Gαs with subsequent activation of protein kinase A 71 
(PKA) signalling (5,6). In hepatocytes, elevated PKA activity suppresses glycolysis and glycogen 72 
synthesis, and enhances gluconeogenesis and glycogenolysis (7,8). However activation of GCGR also 73 
stimulates the phospholipase C-inositol phosphate pathway in hepatocytes via Gq, inducing 74 
intracellular calcium (Ca2+) signalling and stimulating glycogenolysis and gluconeogenesis (6,9). 75 
Although work to unpick glucagon signalling pathways has been underway since the 1970s, it has 76 
focussed primarily on understanding the interactions involved in the downstream effects in the liver 77 
and the pancreas. Less attention has been paid to the role of specific pathways in the extrahepatic 78 
roles of glucagon, namely in appetite regulation and control of energy expenditure. As a prototypical 79 
class B GPCR, the GCGR is desensitised and sequestered in the cytosol following activation (10-12). 80 
The internalised receptor is then either recycled to the cell surface or targeted for degradation. Krilov 81 
et al recently demonstrated that the GCGR recycles to the plasma membrane in a β-arrestin-dependent 82 
manner, and that downregulation of β-arrestins significantly reduces recycling (13,14).  83 
 84 
Understanding the interaction of these pathways may allow ‘biasing’ of signalling to exploit desirable 85 
downstream effects (15,16). A particularly well characterised example of an accessory protein that 86 
clearly alters the pharmacology of GPCRs is a family of single transmembrane proteins known as 87 
Receptor Activity Modifying Proteins (RAMPs). RAMPs were discovered as proteins that interact 88 
with the calcitonin receptor–like receptor (CRLR) and calcitonin receptor (CTR) to give rise to 89 
receptors for different ligands (17). These four ligands (calcitonin, amylin, calcitonin gene-related 90 
peptide and adrenomedullin) bind to two receptors and in the presence of the three RAMPs give rise 91 
to seven different receptor types with distinct pharmacology (18). Additionally, RAMPs have a role in 92 
receptor trafficking including translocation from the endoplasmic reticulum (ER) to the Golgi, 93 
internalisation and recycling of the receptor (19-26). RAMPs have been shown to heterodimerise with 94 
a number of class B and C GPCRs, and influence their function and life-cycle (27,28). The ability of 95 
RAMPs to influence downstream signalling pathways is an exciting concept, as it may enable the 96 
creation of biased agonists that fully exploit the therapeutic potential of clinically important receptors.  97 
 98 
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The functional impact of RAMPs on GCGR pharmacology is not clearly understood. Over ten years 99 
ago, the Christopoulos group showed that the GCGR may interact with RAMP2 (27). Recently, one 100 
study has found that RAMP2 may alter GCGR ligand selectivity and G protein preference using yeast 101 
reporter systems (29). The work presented here is concerned with further understanding the effect of 102 
RAMP2 on the pharmacology of the GCGR in mammalian cells. 103 
 104 
  105 
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MATERIALS AND METHODS 106 
 107 
Peptides 108 
Human GCG, GLP-1 and OXM were purchased from Bachem, Ltd. (UK). GLP-1(7-36)NH2 was the 109 
form used in all experiments, and will now be referred to simply as GLP-1. A dual glucagon/GLP-1 110 
analogue, G(X), was designed in the Department of Investigative Medicine, Imperial College London 111 
and custom synthesised using solid-phase peptide synthesis (Bachem Ltd). G(X) contains identical 112 
amino acid sequences to glucagon from positions 1 to 15 as the N-terminal of glucagon has been 113 
shown to be critical for glucagon receptor binding and activation (30). To create a dual agonist that is 114 
also effective at the GLP-1 receptor, G(X) has been modified to resemble exendin-4.  This peptide, 115 
first isolated from the venom of the lizard Heloderma species, has been found to be a potent agonist at 116 
the human GLP-1 receptor (31,32). Also favorable is its prolonged pharmacokinetic profile compared 117 
to native GLP-1. Therefore, from positions 16-34, amino acid substitutions have been made to 118 
resemble exendin-4. 119 
 120 
Establishing a cellular co-expression system for RAMP2 and GCGR 121 
Chinese hamster ovarian (CHO-K1 cells; GeneBLAzer® GCGR-CRE-bla CHO-K1 cells; K1855A)) 122 
(Invitrogen) cells expressing the GCGR were cultured in DMEM supplemented with 10% FBS, 0.1 123 
mM non-essential amino acids, 25 mM HEPES (pH7.3), 100 IU/ml penicillin, 100 μg/ml 124 
streptomycin and 5 μg/ml blastocidin. This cell line expressed no background RAMP2, as confirmed 125 
using QPCR (CT values >32). The human RAMP2 DNA construct (pCMV6-AC-RAMP2) (Origene, 126 
USA) was transfected into CHO-K1 cells expressing the human GCGR using polyethylenimine (PEI, 127 
Sigma) (33). The cells were transfected with pCMV6-AC-RAMP2 (containing a neomycin resistance 128 
gene) and 9 nitrogen equivalents of PEI. Forty-eight hours later, media was supplemented with 800 129 
μg/ml Geneticin to select cells containing the construct. 130 
To establish a second independent cell line stably expressing RAMP2, CHO-K1 cells expressing the 131 
human GCGR were co-transfected with C-terminally CFP-tagged RAMP2 (Tebu-bio Ltd, UK) and a 132 
plasmid conferring puromycin resistance using lipofectamine 2000 (Thermo Fisher). Forty-eight 133 
hours later, media was supplemented with puromycin 10 μg/ml to select cells containing the construct. 134 
 135 
Confirmation of gene expression 136 
RNA was extracted from cells using a Purelink RNA Mini Kit and DNase set (Invitrogen, UK), 137 
reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 138 
UK) and cDNA amplified by qPCR (probe Hs00359352_m1) (Life Technologies, UK) via a 7900HT 139 
Fast Real-Time PCR System (Applied Biosystems, UK).  140 
 141 
Whole cell binding assays 142 
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Cells were grown up to 70% confluence and resuspended in 1.5 ml assay buffer (25 mM HEPES (pH 143 
7.4), 2 mM MgCl2, 1% BSA, 0.05% (w/v) Tween 20, 0.1 mM diprotin A and 0.2 mM PMSF). 50 µl 144 
of I125-glucagon dissolved in assay buffer at 1000 counts per second (final concentration 5.6 nM), 145 
unlabelled peptide made up in 400 µl of assay buffer and 50 µl of the cell suspension was added to 146 
each microtube, vortexed and incubated at room temperature for 90 minutes. Microtubes were then 147 
centrifuged (15781 x g, 4°C, 3 minutes), supernatant removed, 500µl of assay buffer added, and then 148 
re-centrifuged. The supernatant was again discarded and the pellets measured for γ radiation for 240 149 
seconds (Gamma counter NE1600, NE Technology Ltd, UK). The specific binding (maximal specific 150 
binding minus the non-specific binding) was calculated for each cell line. The binding data was 151 
normalised so that the maximal specific binding (i.e. when no unlabelled peptide was present) was 152 
100%. The percentage specific binding was calculated for each peptide concentration as a percentage 153 
of the specific binding. The half-maximal inhibition concentrations (IC50), a measure of binding 154 
affinity, were then calculated and compared for CHO-K1-GCGR and CHO-K1-GCGR-RAMP2 cells. 155 
IC50 values were calculated using the Graphpad Prism 5.01 (GraphPad Software Inc., USA) using the 156 
following regression fit line: 157 
Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X))) 158 
Where Y=% specific binding and X=concentration of the agonist. 159 
To calculate receptor density (Bmax), binding data was normalised to protein content of the cell 160 
samples, as determined by a bicinchoninic acid assay (Sigma). Bmax was then calculated for using 161 
GraphPad Prism 7.0b (GraphPad Software Inc., USA) using the following regression fit line: 162 
Y=(Bmax*HotnM)/(HotnM + ColdNM + KdNM) + Bottom 163 
 164 
Cell surface expression experiment 165 
CHO-K1 cells overexpressing the human GCGR (± RAMP2) were seeded overnight in 96 well plates 166 
(30,000/well). Following fixation (2% PFA), an in-cell ELISA was performed in non-permeabilised 167 
cells to detect surface GCGR expression. Antibodies used were rabbit primary vs. GCGR N-terminus 168 
(1:200, ab137649 (Abcam, UK) and anti-rabbit IgG HRP-conjugated secondary (1:2000, #15015) 169 
(Active Motif, UK), with 2% BSA block used during in all incubations. TMB substrate (Thermo 170 
Scientific, UK) was added and absorbance read at 450 nm after addition of 1M HCl. Surface GCGR 171 
expression was calculated as absorbance after subtraction of non-specific binding (determined in the 172 
absence of primary antibody) and  normalisation to protein content (BCA assay). 173 
 174 
cAMP accumulation assay for activation of adenylyl cyclase 175 
CHO-K1 cells overexpressing the human GCGR (± RAMP2), plated onto 48 well plates at 40,000 176 
cells/well, were incubated in serum-free media for 1 hour. Peptides were prepared in serum free 177 
DMEM containing 100 µM of IBMX (3-isobutyl-1-methylxanthine, Sigma-Aldrich, UK). The cells 178 
were incubated for 30 minutes with the test peptide after which media was replaced with 110 µl lysis 179 
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buffer (0.1M HCl with 0.5% Triton-X). The lysate was assayed using a direct cyclic AMP ELISA kit 180 
(Enzo Life Sciences, UK), as described in the assay manual. The cAMP response was corrected for 181 
well protein levels (Bradford reagent, Sigma) and expressed as a percentage of response to 10 µM 182 
forskolin.  183 
 184 
Human hepatoma 7 cells overexpressing the human GCGR (Huh7-GCGR) were cultured in DMEM 185 
supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin and 10 μg/ml geneticin 186 
(standard maintenance media). They were plated onto 96 well plates at 20,000 cells/well in standard 187 
maintenance media with transfection reagents for gene silencing (see details below). After 72 hours, 188 
media was aspirated and replaced with 40µl of glucagon at different concentrations, prepared in 189 
serum-free DMEM. The cells were incubated for 30 minutes with the glucagon after which an equal 190 
volume of cAMP lysis buffer (CisBio cAMP Dynamic cell based assay kit) was added to each well. 191 
25µl of lysate was transferred to a HTRF-compatible plate, and 12µl of ‘D’ reagent was added to each 192 
well, followed by 12µl of ‘K’ reagent in accordance with the manufacturer’s instructions. The plate 193 
was read (i3x plate reader (Molecular Devices)) after 1 hour incubation at room temperature and 194 
cAMP response was expressed as a percentage of response to 10µM forskolin.  195 
 196 
The maximal response (Emax) and the half-maximal effective concentrations (EC50) were then 197 
calculated and compared for each peptide tested between CHO-K1-GCGR and CHO-K1-GCGR-198 
RAMP2 cells, and for glucagon between Huh7-GCGR RAMP2 knock down and Huh7-GCGR control 199 
cells. EC50 values were calculated using the following regression fit line: 200 
Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)) 201 
where Y= cAMP response and X=agonist concentration. The curve fitting for the biphasic curves was 202 
done using a variable slope (four parameters) model. 203 
  204 
Intracellular Ca2+ flux assay 205 
The DiscoveRx Ca NWPLUS Assay Kit (DiscoveRx Corporation Ltd, UK) was used as per the 206 
manufacturer’s protocol to detect changes in intracellular Ca2+ in CHO-K1 cells overexpressing the 207 
human GCGR (± RAMP2) in response to glucagon, GLP-1, oxyntomodulin and analogue G(X). 208 
Cells, plated overnight onto 96 well plates at 50,000 cells/well were incubated in 75 µl Ca NWPLUS 209 
working reagent for 1 hour at 37°C. 25 µl of glucagon (or related peptide) was applied from the 210 
reagent plate to the cell plate via the integrated transfer pipettor of a fluorescent microplate reader 211 
(NOVOstar, BMG Labtech Ltd, UK). Fluorescence signal was measured from 5 seconds prior to 30 212 
seconds post injection of agonist. The Ca2+ response was expressed as a percentage of the ATP 213 
response (1 µM).  214 
  215 
β-Arrestin recruitment assay 216 
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PathHunterTM CHO-K1 GCGR β-Arrestin GPCR assay (DiscoveRx Corporation Ltd, UK) was used 217 
to determine the effect of RAMP2 on the potency of GCGR ligands for recruitment of β-Arrestin-1 to 218 
the GCGR. The CHO-K1-βArr-GCGR cells are engineered to detect the interaction of β-arrestin with 219 
the activated GCGR using β-galactosidase fragment complementation. CHO-K1-βArr-GCGR cells 220 
were stably transfected ± RAMP2, as described above. Cells, plated at 100 µl/well into a 96-well plate 221 
were incubated with glucagon, GLP-1, oxyntomodulin, or G(X) (10 µl) for 90 minutes at 37°C and 222 
5% CO2. 55 µl of the PathHunterTM detection reagents was added to each well and the microplate was 223 
incubated at room temperature for 60 minutes.  224 
 225 
SiRNA knockdown 226 
SiRNA knockdown of RAMP2 in CHO-K1-GCGR-RAMP2 and CHO-K1-βArr-GCGR-RAMP2 cells 227 
was performed using pooled siRNA to RAMP2 previously validated by Albertin et al (34). SiRNA 228 
complexes (fully deprotected and desalted, Sigma, UK), added in a single pool (containing 4 229 
duplexes) at final concentrations of 10 nM and 50 nM, were used for transfection with siPORTTM 230 
NeoFXTM (Ambion). siPORT NeoFX (diluted 1:20 into serum-free medium) and RNAs were 231 
combined (1:1) and incubated for 10 min at room temperature. The complexes (200 µl/well) were 232 
then dispensed into a 6-well plate and 2.3 ml of cell suspension containing 150,000 cells/well was 233 
added. The effects on RAMP2 gene expression were assessed 24 hours later.  The effect of 234 
RAMP2 knockdown on GCGR signalling was carried out in a 96-well plate 24 hours later with 235 
volumes adjusted as follows: siRNA 10 µl/well, SiPORT NeoFX 10 µl/well, cell suspension 80 µl 236 
(6000 cells)/well.  237 
 238 
In Huh7-GCGR cells, RAMP2 expression was transiently silenced using small interfering RNA 239 
against human RAMP2 (Ramp2 Silencer Select siRNA, Ambion). Lipofectamine 2000 reagent 240 
(Thermo Fisher) was diluted in Opti-MEM Reduced Serum medium (Thermo Fisher) (0.2µl/5µl) and 241 
then added to siRNA also diluted in Opti-MEM (0.5pmol/5µl) for an incubation period of 5 minutes. 242 
The siRNA-lipofectamine complex (final volume 10µl/well) was dispensed into the wells of a 96-well 243 
plate, and to each well 100µl of cell suspension at 150,000 cells/well was added. Cells were incubated 244 
for 72 hours. Control cells underwent exactly the same procedure except with siRNA with no gene 245 
target (Silencer Select Negative Control No.1 siRNA, Thermo Fisher).  246 
 247 
Confocal microscopy 248 
HEK293 cells were stably transfected with C-terminal GFP-tagged GCGR (Origene, USA) using 249 
Lipofectamine 2000 (Life Technologies Ltd, UK) as per the manufacturer’s protocol. GFP-tagged 250 
GCGR-expressing HEK293 cells were seeded onto sterile coverslips coated with poly-L-lysine in a 6 251 
well plate and transiently transfected ± C-terminally CFP-tagged RAMP2 (Tebu-bio Ltd, UK), non-252 
tagged RAMP2 (Origene, USA) or empty vector (pcDNA3.1). The following day, cells were fixed 253 
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with 2% paraformaldehyde (PFA) (Sigma, UK) and mounted with Vectashield (Vector Laboratories 254 
Ltd, UK). A first set of experiments was carried out using a Crest X-Light spinning disk system 255 
coupled to a Nikon Eclipse Ti microscope and a 63x 1.4 NA oil immersion objective. GFP was 256 
excited using a solid-state at λ = 491 nm laser (Cobalt) and emitted signals collected at λ = 525/25 nm 257 
using a highly-sensitive Orca-Flash4.0 Digital CMOS camera. Due to bleedthrough of the intense 258 
GFP signal into the CFP channel at λ = 440 nm, the latter fluorophore was instead excited slightly off-259 
peak using a solid-state 405 nm laser and emitted signals collected at λ = 525/25 nm. A second set of 260 
experiments was performed using a Zeiss LSM780 confocal microscope and a 63x 1.2 NA water 261 
immersion objective. GFP and CFP were excited using a λ = 488 nm argon laser and emitted signals 262 
collected at λ = 510 - 550 nm using a GaAsP spectral detector. CFP was excited using a λ = 405 nm 263 
diode laser and emitted signals collected at λ = 455-490. Images were post-processed using Zen 264 
software (Zeiss, UK) and subjected to Gaussian smoothing (1.3) to remove noise. Uniform linear 265 
adjustments were applied to contrast and brightness to improve image quality for analysis and 266 
presentation purposes, while preserving the pixel dynamic range and the intersample intensity 267 
differences. Cell surface expression of GCGR-GFP was calculated using the threshold plugin for 268 
ImageJ (NIH).   269 
 270 
Statistical analysis 271 
Emax and EC50 values, derived through 4 parameter curve fit were compared by paired t-test. Prism 272 
Version 5.01 (GraphPad Software Inc. San Diego, USA) was used for statistical analysis. p<0.05 was 273 
conventionally considered statistically significant. Zero concentration points were not included on the 274 
graphs in figures 2-6 for ease of viewing. Comparison of RAMP2 expression between two groups was 275 
performed using either unpaired or paired Student’s t-test, or where multiple comparisons where 276 
required, one-way ANOVA followed by Bonferroni’s multiple comparisons post hoc test. Controls 277 
with no peptide added were included in all experiments. 278 
 279 
  280 
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RESULTS 281 
 282 
Confirmation of transfection of CHO-K1-GCGR and CHO-K1-βArr-GCGR cells with RAMP2 283 
Successful transfection into CHO-K1-GCGR cells of the pCMV6-AC-RAMP2 plasmid was 284 
confirmed by qPCR. Subsequently, a second CHO-K1 cell line expressing the GCGR containing the 285 
β-arrestin recruitment reporter signal (CHO-K1-βArr-GCGR) was also transfected with RAMP2 286 
(Supplementary Figures 1A and B).  287 
Similarly, successful transfection of CHO-K1-GCGR cells with C-terminally CFP-tagged RAMP2 288 
(Tebu-bio Ltd, UK) was confirmed by qPCR. H-RAMP2 was undetectable in the control cell line but 289 
expressed in the CHO-K1-GCGR-CFP-RAMP2 cells. 290 
 291 
RAMP2 reduces specific glucagon binding at the GCGR 292 
When specific glucagon binding to the GCGR was compared in RAMP2 positive and negative CHO-293 
K1 cells, it was found to be 10-fold lower in the presence of RAMP2 (see Figure 1A). This was 294 
despite the protein content being similar in both groups (see Figure 1B). 295 
 296 
Glucagon bound to the GCGR with an IC50 of 1.403 nM. This was not significantly altered when the 297 
GCGR was co-expressed with RAMP2 (Figure 1C, table 1). As expected, GLP-1 had poor affinity for 298 
the GCGR with an IC50 of >10000 nM (Figure 1D). Oxyntomodulin and analogue G(X) showed a 7-299 
fold and 2.5 fold lower affinity for the GCGR than the native peptide, respectively (Figures 1E and F). 300 
Similar to glucagon, the presence of RAMP2 had no effect on the binding affinity at the GCGR for 301 
GLP-1, oxyntomodulin or analogue G(X). 302 
 303 
To ensure that these findings were attributable to co-expression of RAMP2 with the GCGR, a second 304 
independent cell line with RAMP2 stably upregulated was investigated (CHO-K1-GCGR-CFP-305 
RAMP2) and compared to a cell line transfected in parallel with a control (pcDNA3.1) plasmid. As 306 
with the first cell line (CHO-K1-GCGR-RAMP2), the binding affinity of glucagon for its receptor 307 
was not altered with the upregulation of RAMP2 (IC50 4.377nM with CFP-RAMP2 vs 5.123nM 308 
without (p=0.16)) (Supplemental Figure 2A), however the density of GCGR binding sites (Bmax) was 309 
significantly lower in the cell line with upregulated RAMP2 (p=0.0069) (Supplemental Figure 2B).  310 
 311 
RAMP2 reduces cell surface expression of the GCGR 312 
Using an in-cell ELISA, surface GCGR expression was detected in non-permeabilised CHO-K1-313 
GCGR cells (± RAMP2) (Supplementary Figure 3). GCGR cell surface expression was significantly 314 
reduced in cells expressing RAMP2. 315 
 316 
RAMP2 reduces potency and increases efficacy of the Gαs pathway at the GCGR 317 
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To assess whether RAMP2 affected the Gαs pathway, cAMP accumulation was measured in its 318 
presence/absence in CHO-K1 cells (Figure 2, Table 2). In control cells, the highest concentrations of 319 
peptide resulted in cAMP accumulation lower than the Emax, which is a well described desensitisation 320 
effect (14). In the presence of RAMP2, glucagon, oxyntomodulin and analogue G(X) increased the 321 
EC50 i.e. RAMP2 reduced the potency of these ligands for GCGR Figure 2A, C and D). When the 322 
GCGR was stimulated by oxyntomodulin or analogue G(X), the Emax (efficacy) was increased in the 323 
presence of RAMP2. The EC50 and Emax were not calculable for GLP-1 response at the concentrations 324 
used (Figure 2B). There was no significant difference in cAMP responses to forskolin between control 325 
and RAMP2 expressing cells (0.136 (± 0.01) vs. 0.140 (± 0.01), relative absorbance units 326 
respectively; p=0.20). 327 
 328 
To investigate whether changes in cAMP accumulation at the GCGR conferred by RAMP2 were 329 
generalizable to other cell types, cAMP accumulation in response to glucagon was measured in Huh7-330 
GCGR cells with or without RAMP2 knockdown. Huh7-GCGR cells express a low level of 331 
endogenous RAMP2 and silencing conferred approximately 70% knock down. There was no 332 
statistically significant change in glucagon potency in Huh7-GCGR cells with RAMP2 knockdown 333 
and a trend towards a lower Emax, although this was not statistically significant (Supplementary Figure 334 
4).  335 
 336 
RAMP2 reduces efficacy of the Gq pathway at the GCGR 337 
To assess the effect of RAMP2 on the Gαq pathway, intracellular Ca2+ flux was measured in real time 338 
in CHO-K1 cells. For glucagon and oxyntomodulin, the Ca2+ response was attenuated when cells 339 
expressing the glucagon receptor were co-expressed with RAMP2, as demonstrated by a significantly 340 
lower Emax (Figure 3A, B, C and E). RAMP2 also appeared to lower the response to G(X), however, 341 
as the maximal Ca2+ response was not achieved with cells expressing GCGR alone, and Emax could not 342 
be determined (Figure 3F). Similarly, the EC50 and Emax were not calculable for GLP-1 response at the 343 
concentrations used (Figure 3D). EC50 was unchanged in the presence of RAMP2 for all ligands 344 
(Table 2). There was no significant difference in Ca2+ responses to ATP between control and RAMP2 345 
expressing cells (RFU fold increase from baseline 1.81 (± 0.08) vs. 1.84 (± 0.10) respectively; 346 
p=0.77) (Figures 3A and B). 347 
 348 
RAMP2 abolishes β-Arrestin recruitment at the GCGR  349 
For all ligands (glucagon, GLP-1, oxyntomodulin and analogue G(X)), β-arrestin recruitment did not 350 
occur in CHO-K1 cells expressing both GCGR and RAMP2 (Figure 4). 351 
 352 
RAMP2 knockdown partially restores GCGR functioning for the Gαs and Gq pathways 353 
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Efficient siRNA knockdown of RAMP2 was achieved with both 10 nM and 50 nM siRNA pools 354 
(Figure 5A). siRNA knockdown of RAMP2 in CHO-K1-GCGR-RAMP2 cells resulted in a trend 355 
toward restoration of cAMP EC50 and Emax to levels seen with control cells (CHO-K1-GCGR cells), 356 
however, they were not significantly different to control or RAMP2 (without siRNA) cells (Figure  357 
5B). A similar finding was demonstrated for Ca2+ fluxes (Figure 5C). The EC50 and Emax data is 358 
summarised in Table 3.  359 
 360 
The GCGR and RAMP2 colocalise and the GCGR is internalised in the presence of RAMP2 361 
High resolution confocal microscopy showed that GCGR-GFP and RAMP2-CFP co-localised as 362 
puncta within the cytosol of HEK293 (Figure 6A). In cells where RAMP2 was not overexpressed, 363 
GCGR-GFP remained predominantly at the cell surface/membrane (Figure 6B). This was not due to 364 
bleedthrough of GCGR-GFP fluorescence into the RAMP2-CFP channel, since signal could not be 365 
detected in RAMP2 negative/GCGR positive cells (Figure 6C). Overexpression of non-native protein 366 
(pcDNA3.1) did not interfere with the distribution of the GCGR-GFP, which remained almost 367 
exclusively at the membrane (Figure 6D), whereas non-tagged RAMP2 led to a significant decrease in 368 
receptor at the cell membrane (Fig. 6E). This demonstrates that protein expression per se is unlikely 369 
to interfere with GCGR localisation. Thus, overexpression of RAMP2-CFP or RAMP2 consistently 370 
leads to a decrease in cell surface GCGR-GFP (Fig. 6F).  371 
  372 
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DISCUSSION  373 
 374 
It has previously been demonstrated by immunofluorescence confocal microscopy that RAMP2 may 375 
interact with the glucagon receptor. We have investigated the functional effect of this possible 376 
interaction by looking specifically at the effect of RAMP2 on: 1) ligand binding at the GCGR; 2) 377 
GCGR cell signalling; and 3) GCGR subcellular distribution. Co-expression of RAMP2 with GCGR 378 
did not alter the binding affinity of glucagon or its related peptides. However, the presence of RAMP2 379 
had a marked effect on signalling via the Gαs and Gq pathways, as well as β-arrestin recruitment. 380 
Furthermore, RAMP2 appears to co-localise with the GCGR and influence its subcellular distribution. 381 
 382 
Interaction between calcitonin family receptors and the individual RAMP proteins alters both ligand 383 
binding affinity and the intracellular signalling pathways engaged (17,35,36). By contrast, we found 384 
that expression of RAMP2 with the GCGR did not cause a significant alteration in the binding affinity 385 
of glucagon and its related peptides in whole cells. However, competition binding experiments using 386 
125I-glucagon as the radioligand revealed that co-expression of RAMP2 resulted in a ten-fold 387 
reduction in GCGR binding sites when compared with those determined in the absence of RAMP. 388 
This reduction in specific binding of glucagon may be due to reduced receptor expression at the cell 389 
surface. This could have been a direct effect of the interaction of RAMP2 and the GCGR resulting in 390 
internalisation. Alternatively, it might be an indirect effect if, for example, RAMP2 influences GCGR 391 
cell surface expression via its effect on β-arrestin recruitment. 392 
 393 
The presence of RAMP2 completely abolished β-arrestin recruitment. This finding was consistent for 394 
glucagon as well as GLP-1, oxyntomodulin and G(X). One possible explanation is that RAMP2 395 
interacts with the GCGR at the same site as β-arrestin binds or causes steric hindrance, thereby 396 
disrupting β-arrestin recruitment. Krilov et al have shown that β-arrestins are crucial for the recycling 397 
of the GCGR (13) and, therefore, loss of β-arrestin recruitment may result in reduced cell surface 398 
expression of the GCGR when RAMP2 is present. Alternatively, reduced cell surface expression of 399 
GCGR may be the primary effect of RAMP2 and this may in turn prevent β-arrestin recruitment.  400 
 401 
Co-expression of RAMP2 with the GCGR also altered the intracellular signalling properties of the 402 
receptor in CHO-K1-GCGR cells, with the same effects seen for all agonists tested. With regards to 403 
the Gαs pathway, the presence of RAMP2 caused a reduction in potency and increase in efficacy. In 404 
Huh7-GCGR cells, the knockdown of RAMP2 resulted in no change in potency and a trend towards 405 
decreased efficacy. Whether this is a result of a change in availability of binding sites is yet to be 406 
determined. In contrast to our findings, Weston et al found that RAMP2 increases potency of the 407 
cAMP response at the GCGR (29). One possible explanation for these different findings could be the 408 
different cell lines used. Weston et al overexpressed RAMP2 in HEK cells that already express 409 
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endogenous RAMP2, whereas we overexpressed RAMP2 in CHO-K1 cells that do not express 410 
RAMP2. It has previously been shown that interaction of the CTR with RAMPs, especially RAMP2, 411 
is sensitive to the cellular background in which it is expressed, suggesting that other cellular 412 
components, such as G proteins, are likely to contribute to RAMP-receptor interactions (36). 413 
 414 
The increase in efficacy of cAMP production observed with RAMP2 is intriguing. This enhancement 415 
in cAMP response is all the more striking as it is in the face of an apparent reduction of cell surface 416 
expression of GCGR. The simplest interpretation is that by some mechanism, RAMP2 increases the 417 
accessibility of the receptor to the G-protein (37). Alternatively, RAMP2 may inhibit the 418 
desensitisation response that is classically seen with the GCGR, involving phosphorylation of 419 
receptors by GPCR kinases (GRKs) and binding of β-arrestins, which uncouple receptors from G-420 
proteins (38). We speculate that the GCGR-RAMP2 interaction causes loss of desensitisation, which 421 
may be driven by inhibition of β-arrestin recruitment. Indeed, RAMPs are crucial in the post-422 
endocytic sorting of the CRLR, suggesting a broader regulatory role for RAMPs in receptor 423 
trafficking (24,25). 424 
 425 
On examination of the Gq pathway, intracellular Ca2+ fluxes were found to be attenuated in 426 
the presence of RAMP2. Interestingly, preferential coupling to Gαs versus Gq has been reported for 427 
AMY1 and AMY3 receptors, but not AMY2 (39). The finding that cAMP signalling is specifically 428 
augmented and Ca2+ signalling attenuated by RAMP2 at the GCGR is important because the classic 429 
coupling pathway associated with GCGR activation has always been thought to be the stimulation of 430 
cAMP accumulation. Moreover, the presence or absence of endogenous RAMP2 may account for 431 
discrepancies in previous studies examining the signalling mechanisms engaged by the GCGR. 432 
Whether this is tissue-specific and dependent on the prevailing physiological conditions is yet to be 433 
seen. 434 
 435 
Visualisation of RAMP2 and the non-ligand bound GCGR using confocal microscopy revealed two 436 
key findings. Firstly, it is demonstrated that RAMP2 and the GCGR show some co-localisation, 437 
although super-resolution approaches will be needed to confirm this, as well as delineate the 438 
compartment(s) involved. Secondly, in the presence of RAMP2, there was reduced GCGR cell 439 
surface expression. This is consistent with the competition binding and ELISA experiments, which 440 
found reduced binding of 125I-GCG in the presence of RAMP2. These findings appear to be at odds 441 
with the work done by Christopoulos et al which reported that, when co-expressed with GCGR, 442 
RAMP2 translocates to the cell surface. A number of differences exist in the experimental approach 443 
between this current study and that of Christopoulos. Firstly, in their study only the RAMPs, and not 444 
the GCGR, were tagged so it was not possible to comment on where the receptor was trafficked to. 445 
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Secondly, in the Christopoulos study, RAMP2 was N-terminally tagged with haemagglutinin whereas 446 
here both C-terminally CFP-tagged and native RAMP2 was utilised. It is the N-terminal that contains 447 
the natural, predicted signal peptide sequence of RAMP2 and therefore this may have had a bearing 448 
on expression of RAMP2. In line with our findings, using C-terminal receptor-fluorescent protein 449 
fusion constructs and cell surface ELISAs of myc-tagged receptors, Weston et al found that 450 
expression of RAMP2 caused a non-significant decrease in cell surface expression of GCGR (29). To 451 
ensure that the agonist-stimulated internalization response is not due to glucagon in the serum used to 452 
culture these cells, with amplification in the presence of RAMP2, further experiments could be 453 
performed with a GCGR antagonist or serum-free medium, or alternatively excess glucagon. 454 
 455 
Taken together, this work demonstrates that RAMP2 may affect the cell signalling pathways of the 456 
GCGR as well as its trafficking within the cell. There are two possible mechanisms by which RAMP2 457 
could influence GCGR pharmacology. A direct on binding epitopes of the relevant ligands is possible. 458 
Alternatively, RAMP2 could act indirectly by altering the conformation of the GCGR.  459 
 460 
This work has added to our understanding of GCGR’s physiological function and how this may be 461 
modified by an allosteric modulator, RAMP2. This could be important in developing new therapeutic 462 
avenues for the treatment of obesity and diabetes. Allosteric modulation through the RAMP2 system 463 
may allow ‘biasing’ of the signalling pathways to exploit the desirable downstream effects, thus 464 
informing the construction of new peptide analogues with selective agonist activities. For example, 465 
these might incorporate therapeutically desirable properties such as appetite suppression and increase 466 
in energy expenditure, without unwanted properties such as increasing hepatic glucose output and 467 
hyperglycaemia.  468 
 469 
The work conducted thus far has been in GCGR overexpressing cell lines. The logical next step would 470 
be to use primary cells in tissue relevant to glucagon receptor physiology. It would be interesting to 471 
use CRISPR-Cas9 to delete/replace the endogenous loci in a beta or hepatocyte cell line, thus leading 472 
to stable and physiological GCGR expression levels in the presence or absence of RAMP and study 473 
function. Additionally, endogenous tissue co-expression of RAMP2 and GCGR has not yet been 474 
investigated. RAMP mRNA tissue expression using northern blot analysis was reported initially by 475 
McLatchie et al on their first discovery of RAMPs (17). However, GCGR-relevant tissues such as 476 
brown adipose tissue, hypothalamus and the nodose ganglion were not specifically examined. An 477 
additional question is whether the RAMP2-GCGR interaction is controlled in a physiological setting. 478 
It would be important to determine what process controls this and what effect it has on glucagon 479 
signalling. Co-expression may occur in some tissues under certain conditions and not others as 480 
expression of RAMP2 may be controlled by the prevailing physiological conditions, for example, 481 
glucose and insulin levels.  482 
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 483 
In conclusion, RAMP2 can affect the cell signalling pathways of the GCGR as well as its trafficking 484 
within the cell. The effect that RAMP2 has on the GCGR and how this translates in vivo is yet to be 485 
determined. 486 
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TABLE AND FIGURE LEGENDS 641 
TABLE 1.  Binding affinities of A) glucagon, B) GLP-1, C) oxyntomodulin and D) analogue G(X) to 642 
the human glucagon receptor. Whole CHO-K1-GCGR cells ± RAMP2 were used.  I125-glucagon was 643 
used as the competing peptide in all assays and IC50 values were calculated as a mean of four separate 644 
experiments (except for GLP-1 where n=2) with each peptide concentration performed in duplicate or 645 
triplicate during an individual experiment. Errors shown are ±SEM. 646 
 647 
TABLE 2. Summary of cAMP accumulation and Ca2+ data for glucagon, GLP-1, oxyntomodulin and 648 
analogue G(X) at the glucagon receptor. EC50 is defined as the concentration of agonist required to 649 
cause 50% of the maximal possible effect of that agonist. Emax is the maximal response of the agonist 650 
expressed as a percentage of maximal positive control response. Values calculated as a mean from a 651 
minimum of four separate experiments (except for GLP-1 n=2). Values shown as mean ± SEM. * 652 
p<0.05 and ** p<0.01 comparing CHO-K1-GCGR  cells ± RAMP2. 653 
 654 
TABLE 3. The effect of siRNA knockdown of RAMP2 in CHO-K1-GCGR-RAMP2 cells on cAMP 655 
accumulation and Ca2+ flux for glucagon at the glucagon receptor. EC50 is defined as the concentration 656 
of agonist required to cause 50% of the maximal possible effect of that agonist. Emax is the maximal 657 
response of the agonist expressed as a percentage of maximal positive control response. Values shown 658 
as mean ± SEM. * p<0.05 and ** p<0.01 comparing CHO-K1-GCGR  cells ± RAMP2. EC50 and Emax 659 
values for siRNA treated cells were not significantly different to control or RAMP2 positive cells. 660 
Values calculated as a mean from a minimum of two separate experiments. Errors shown are ±SEM. 661 
 662 
FIGURE 1. A) Specific binding of I125-glucagon to the GCGR in CHO-K1-GCGR cells ± RAMP2 663 
(p<0.0001). B) The protein content was determined by Bradford assay (used here as a surrogate 664 
marker for the number of cells) for CHO-K1-GCGR cells ± RAMP2. Whole cell binding of C) 665 
glucagon, D) GLP-1, E) oxyntomodulin and F) analogue G(X) to the human glucagon receptor.  666 
Whole CHO-K1-GCGR cells ± RAMP2 were used. I125-glucagon was used as the competing peptide 667 
in all assays and IC50 values were calculated as a mean of four separate experiments (except for GLP-668 
1 where n=2), with each peptide concentration performed in duplicate or triplicate during an 669 
individual experiment. Values represent the mean ±SEM. 670 
 671 
FIGURE 2. Human glucagon receptor-mediated cAMP accumulation in CHO-K1-GCGR cells ± 672 
RAMP2 by ligands A) glucagon, B) GLP-1, C) oxyntomodulin and D) analogue G(X). Each peptide 673 
concentration was tested in duplicate or triplicate in each experiment. Values calculated as a mean 674 
from a minimum of four separate experiments (unless stated otherwise). * p<0.05 comparing the Emax 675 
for CHO-K1-GCGR cells ± RAMP2. Values represent the mean ±SEM. 676 
 677 
FIGURE 3. Intracellular Ca2+ flux in response to varying doses of glucagon in real-time in CHO-K1-678 
GCGR cells A) without RAMP2 and B) with RAMP2 (measured in Relative Fluorescence Unit 679 
(RFU) fold increase from baseline RFU). Human glucagon receptor-mediated Ca2+ flux in CHO-K1-680 
GCGR cells ± RAMP2 by ligands C) glucagon, D) GLP-1 and E) oxyntomodulin and F) analogue 681 
G(X). Each peptide concentration was tested in duplicate or triplicate in each experiment. Values 682 
calculated as a mean from a minimum of four separate experiments (unless stated otherwise). ** 683 
p<0.01 comparing the Emax for CHO-K1-GCGR cells ± RAMP2. Values represent the mean ±SEM. 684 
 685 
FIGURE 4. Human glucagon receptor-mediated β-arrestin recruitment in CHO-K1- βArr-GCGR 686 
cells ± RAMP2 by endogenous ligands A) glucagon, B) GLP-1 and C) oxyntomodulin and D) 687 
analogue G(X). Each peptide concentration was tested in duplicate or triplicate in each experiment. 688 
Results are expressed as a percentage of maximal glucagon-mediated β-arrestin recruitment. Values 689 
calculated as a mean from a minimum of four separate experiments. **** p<0.0001 comparing the 690 
Emax for CHO-K1-βArr-GCGR cells ± RAMP2. Values represent the mean ±SEM. 691 
 692 
FIGURE 5. Effect of siRNA knockdown of RAMP2 in CHO-K1-GCGR-RAMP2 cells on A) 693 
hRAMP2 expression by qPCR, B) cAMP accumulation and C) Ca2+ flux in response to glucagon. 694 
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Each peptide concentration was tested in duplicate or triplicate in each experiment. Values calculated 695 
as a mean from a minimum of two separate experiments. **p<0.01 ***p<0.001. Values shown are 696 
±SEM. 697 
 698 
FIGURE 6. Effect of RAMP2 on GCGR localisation. A) Representative image showing that GCGR-699 
GFP (green) and RAMP2-CFP (red) can colocalise (yellow) within the cytosolic compartment 700 
following their overexpression (n = 15 cells) (zooms are inset to the right). B) Representative image 701 
showing that GCGR-GFP expression is predominantly at the membrane/surface in HEK cells without 702 
RAMP2 overexpression (n = 8 cells). C) A negative control indicating that the 405 nm laser does not 703 
excite GCGR-GFP (n = 3 cells). D) Overexpression of non-native protein (pcDNA3.1) does not 704 
interfere with the distribution of the GCGR-GFP, which remains at the membrane (n = 7 cells). E) 705 
Overexpression of non-tagged RAMP2 leads to redistribution of GCGR-GFP into the cell (n = 7 cells) 706 
(zooms are inset to the right). F) Bar graph showing that overexpression of either RAMP2-CFP or 707 
non-tagged RAMP2, but not pcDNA3.1, leads to a significant reduction in cell surface GCGR-GFP 708 
expression (**p<0.01) (n = 8-14 cells from at least three independent experiments). Scale bar = 10 709 
µm. Values represent the mean ± SEM.  710 
 711 
SUPPLEMENTARY FIGURE 1. Expression of RAMP2 in control cells and cells transfected with 712 
the pCMV6-AC-RAMP2 plasmid in two different cell lines A) CHO-K1-GCGR cells and B) CHO-713 
K1-βArr-GCGR cells. CHO-K1-GCGR±RAMP2 cells were used for cAMP accumulation and Ca2+ 714 
flux experiments while CHO-K1-βArr-GCGR±RAMP2 cells, containing the β-Arrestin recruitment 715 
reporter signal, were used in the β-Arrestin recruitment assays. Values calculated as a mean from a 716 
minimum of two separate experiments. ****p<0.0001. Errors shown are ±SEM. 717 
 718 
SUPPLEMENTARY FIGURE 2. A) Whole cell binding of glucagon to the human glucagon 719 
receptor, with I125-glucagon used as the competing peptide.  Whole CHO-K1-GCGR cells ± CFP-720 
RAMP2 were used. Data is presented as mean and standard error of mean of four separate 721 
experiments with each peptide concentration performed in duplicate or triplicate during an individual 722 
experiment. B) Whole cell binding of glucagon to the human glucagon receptor, with I125-glucagon 723 
used as the competing peptide.  Whole CHO-K1-GCGR cells ± CFP-RAMP2 were used. Data is 724 
presented as mean and standard error of mean of Bmax as calculated from three separate experiments 725 
with each peptide concentration performed in duplicate or triplicate during an individual 726 
experiment.**p<0.01) 727 
 728 
SUPPLEMENTARY FIGURE 3. Cell surface GCGR expression in CHO-K1-GCGR cells ± 729 
RAMP2. Surface GCGR expression was calculated as absorbance after subtraction of non-specific 730 
binding (determined in absence of primary antibody) and  normalisation to protein content (BCA 731 
assay). Values expressed in arbitrary units (the signal divided by the protein content in mg/ml). 732 
Values calculated as a mean from five separate experiments. * p<0.05 comparing CHO-K1-GCGR 733 
cells ± RAMP2. Values represent the mean ±SEM. 734 
SUPPLEMENTARY FIGURE 4. Human glucagon receptor-mediated cAMP accumulation in 735 
Huh7-GCGR cells by glucagon ± RAMP2 knockdown. Each peptide concentration was tested in 736 
duplicate or triplicate in each experiment. Summary of EC50 and Emax data is shown in the 737 
accompanying table. Values calculated as a mean from three separate experiments. Values shown as 738 
mean ± SEM.  739 
 740 
 741 
 742 
  743 
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Table 1 745 
 746 
 747 
 748 
 749 
 750 
 751 
 752 
 753 
TABLE 1.  Binding affinities of A) glucagon, B) GLP-1, C) oxyntomodulin and D) analogue G(X) to 754 
the human glucagon receptor.  Whole CHO-K1-GCGR cells ± RAMP2 were used.  I125-glucagon was 755 
used as the competing peptide in all assays and IC50 values were calculated as a mean of four separate 756 
experiments (except for GLP-1 where n=2) with each peptide concentration performed in duplicate or 757 
triplicate during an individual experiment. Errors shown are ±SEM. 758 
 759 
  760 
IC50 GCGR Control GCGR + RAMP2 
Glucagon 1.403 nM ±0.21 0.768 nM ±0.15 
GLP-1 >10000 nM >10000 nM 
OXM 10.43 nM ±2.59 3.873 nM ±0.93 
G(X) 3.381 nM ±1.07 3.984 nM ±1.81 
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Table 2 761 
 762 
 763 
 764 
TABLE 2. Summary of cAMP accumulation and Ca2+ data for glucagon, GLP-1, oxyntomodulin and 765 
analogue G(X) at the glucagon receptor. EC50 is defined as the concentration of agonist required to 766 
cause 50% of the maximal possible effect of that agonist. Emax is the maximal response of the agonist 767 
expressed as a percentage of maximal positive control response. Values calculated as a mean from a 768 
minimum of four separate experiments (except for GLP-1 n=2). Values shown as mean ± SEM. * 769 
p<0.05 and ** p<0.01 comparing CHO-K1-GCGR  cells ± RAMP2. 770 
  771 
 cAMP accumulation intracellular  Ca2+ flux 
CHO-K1-GCGR  
cells 
CHO-K1-GCGR  
cells +RAMP2 
CHO-K1-GCGR  
cells 
CHO-K1-GCGR  
cells +RAMP2 
Glucagon EC50 
(nM) 
0.161 ± 0.063 1.263 ± 0.289* 256.5  ± 27.46 314.1 ± 37.03 
 Emax 
(%) 
34.04 ± 6.897 54.50 ± 9.781 109.0 ± 2.215 57.7 ± 1.313** 
GLP-1 EC50 
(nM) 
N/A N/A N/A N/A 
 Emax 
(%) 
N/A N/A N/A N/A 
Oxyntomodulin EC50 
(nM) 
1.089 ± 0.382 12.97 ± 8.544* 109.6 ± 11.5 156.8 ± 43.21 
 Emax 
(%) 
34.69 ± 6.815 46.23 ± 7.409* 108 ± 9.28 64 ± 12.3** 
Analogue G(X) EC50 
(nM) 
0.074 ± 0.056 0.538 ± 0.065* N/A 656.6 ± 35.0 
 Emax 
(%) 
31.11 ± 3.578 65.43 ± 7.027* N/A 62.5 ± 6.06 
24 
 
Table 3 772 
 773 
 774 
 775 
 776 
 777 
TABLE 3. The effect of siRNA knockdown of RAMP2 in CHO-K1-GCGR-RAMP2 cells on cAMP 778 
accumulation and Ca2+ flux for glucagon at the glucagon receptor. EC50 is defined as the concentration 779 
of agonist required to cause 50% of the maximal possible effect of that agonist. Emax is the maximal 780 
response of the agonist expressed as a percentage of maximal positive control response. Values shown 781 
as mean ± SEM. * p<0.05 and ** p<0.01 comparing CHO-K1-GCGR cells ± RAMP2. EC50 and Emax 782 
values for siRNA treated cells were not significantly different to control or RAMP2 positive cells. 783 
Values calculated as a mean from a minimum of two separate experiments. Errors shown are ±SEM. 784 
 785 
 786 
   
CHO-K1-GCGR  
cells 
CHO-K1-GCGR  
cells +RAMP2 
CHO-K1-GCGR  
cells +RAMP2 
SiRNA 10nM 
CHO-K1-GCGR  
cells +RAMP2 
SiRNA 50nM 
cAMP 
accumulation 
EC50 
(nM) 
0.161 ± 0.063 1.263 ± 0.289* 0.778  ± 0.018 0.846  ± 0.018 
 Emax 
(%) 
34.04 ± 6.897 54.50 ± 9.781 50.46  ± 0.96 51.26  ± 0.11 
intracellular  
Ca2+ flux 
EC50 
(nM) 
256.5  ± 27.46 314.1 ± 37.03 387.5  ± 108.5 295.3  ± 54.2 
 Emax (%) 109.0 ± 2.215 57.7 ± 1.313** 74.13  ± 2.5 70.23  ± 1.5 
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